KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to -$167.6 million.

  • Vir Biotechnology's Cash from Operations rose 228.01% to -$167.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$453.5 million, marking a year-over-year increase of 280.81%. This contributed to the annual value of -$446.4 million for FY2024, which is 4268.61% up from last year.
  • Vir Biotechnology's Cash from Operations amounted to -$167.6 million in Q3 2025, which was up 228.01% from -$120.2 million recorded in Q2 2025.
  • Vir Biotechnology's Cash from Operations' 5-year high stood at $960.1 million during Q2 2022, with a 5-year trough of -$389.2 million in Q2 2023.
  • In the last 5 years, Vir Biotechnology's Cash from Operations had a median value of -$89.5 million in 2021 and averaged $1.3 million.
  • As far as peak fluctuations go, Vir Biotechnology's Cash from Operations soared by 141645.83% in 2021, and later plummeted by 40725.67% in 2023.
  • Vir Biotechnology's Cash from Operations (Quarter) stood at $7.7 million in 2021, then soared by 356.48% to $35.1 million in 2022, then plummeted by 407.26% to -$107.9 million in 2023, then rose by 18.8% to -$87.6 million in 2024, then tumbled by 91.21% to -$167.6 million in 2025.
  • Its last three reported values are -$167.6 million in Q3 2025, -$120.2 million for Q2 2025, and -$78.1 million during Q1 2025.